TACC3 and head and neck squamous cell carcinoma: In SCCHN, the FGFR3-TACC3 fusion was identified and FGFR mutations were studied mainly in HPV-positive cases [6, 16, 17], suggesting this RTK may serve as a target for treatment in this specific SCCHN population.